ライフサイエンスコーパス: breast biopsy

1 a benign pathology result from image-guided breast biopsy.

2 ollowed within 6 months by benign excisional breast biopsy.

3 Breast adipose tissue was collected during breast biopsy.

4 n is removed at directional, vacuum-assisted breast biopsy.

5 erences of the value on avoiding any form of breast biopsy.

6 (mean age, 48.5 years +/- 8.7) scheduled for breast biopsy.

7 breast cancer; 17% of the women had a prior breast biopsy.

8 e for oncoprotein-related signaling in human breast biopsy.

9 ily history of breast cancer, and history of breast biopsy.

10 y be able to improve the PPV of image-guided breast biopsy.

11 or use in magnetic resonance vacuum-assisted breast biopsy.

12 , should be obtained with 14-gauge US-guided breast biopsy.

13 lpable breast lesions is needle localization breast biopsy.

14 383 lesions) were referred for stereotactic breast biopsy.

15 e patients had undergone previous excisional breast biopsies.

16 eterozygosity (HRD-LOH) in pretreatment core breast biopsies.

17 l and malignant tissues from human colon and breast biopsies.

18 CF-7 breast cancer cells as well as in human breast biopsies.

19 ased the number of their recommendations for breast biopsies.

20 ethod for performing PEM-guided stereotactic breast biopsies.

21 d from women scheduled to undergo diagnostic breast biopsies.

22 ember 2011 and May 2014 from test sets of 60 breast biopsies (240 total cases, 1 slide per case), inc

23 268 surgical excisional and 796 percutaneous breast biopsies (290 US-guided, 370 stereotactically gui

24 One hundred twelve women awaited breast biopsy; 42, hepatic chemoembolization for cancer;

25 (adjusted OR, 1.07 [CI, 1.06 to 1.09]), and breast biopsy (adjusted OR, 1.10 [CI, 1.08 to 1.12]).

26 was performed in women scheduled to undergo breast biopsy after institutional review board approval

27 However, serial breast biopsy analysis in nonpregnant premenopausal wome

28 US is routinely used to guide breast biopsies and is also emerging as a supplemental s

29 h percutaneous gastrostomy, mammography with breast biopsy and excision, and prostate biopsy with pro

30 e the optimal "base case" risk threshold for breast biopsy and perform sensitivity analysis.

31 r ultrasound-guided, large-core percutaneous breast biopsy and the evolution of mammotomy, radiologis

32 e optimal general threshold for image guided breast biopsy and the sensitivity of this threshold to v

33 scriptions of the advantages of percutaneous breast biopsy and the techniques of performing breast in

34 esonance (MR) imaging-guided vacuum-assisted breast biopsy and to explore the imaging, demographic, a

35 tumors, when compared with benign and normal breast biopsies, and a relationship to lymph node invasi

36 history of breast cancer, number of previous breast biopsies, and percentage density (PD).

37 diagnostic mammographic work-up, breast US, breast biopsy, and clinical follow-up were retrospective

38 ss index (>25 vs 18.5-25), history of benign breast biopsy, and nulliparity or age at first birth (>/

39 non-SLN removed, tumor palpability, type of breast biopsy, and SLN injection technique were not sign

40 amily history of breast cancer or a previous breast biopsy; and all women aged 40 to 79 years with bo

41 Currently, 80% of open breast biopsies are benign, resulting in excessive econo

42 umber of nonpalpable abnormalities requiring breast biopsy are being identified due to the widespread

43 Most women undergoing breast biopsy are found not to have cancer.

44 Metallic clips placed during core-needle breast biopsy are intended to mark the biopsy site when

45 family history of breast cancer, history of breast biopsy, BBD diagnoses, and breast density in the

46 ultrasound imaging system for use in making breast biopsy decisions prompted considerable interest i

47 Women with benign breast biopsies demonstrating both HER-2/neu amplificati

48 per case, 92.3% (95% CI, 91.4% to 93.1%) of breast biopsy diagnoses would be verified by reference c

49 cer status was ascertained on the basis of a breast biopsy done within 15 months after study entry or

50 ve screening mammogram that led to 19 benign breast biopsies, eight refused work-up, and three experi

51 of a woman's age, breast density, history of breast biopsy, family history of breast cancer, and beli

52 A core needle breast biopsy finding of ADH for nonpalpable lesions the

53 an spectroscopy for guidance of stereotactic breast biopsies for microcalcifications are also discuss

54 th breast cancer who underwent contralateral breast biopsy for clinically or mammographically detecte

55 eness of hematoma-directed ultrasound-guided breast biopsy for nonpalpable lesions seen by magnetic r

56 reveals that 2% is the optimal threshold for breast biopsy for patients between 42 and 75 however the

57 tably, proliferation was markedly reduced in breast biopsies from BRCA1-mutation carriers who were tr

58 rived from them--obtained ex vivo from fresh breast biopsies from patients undergoing stereotactic br

59 907 patients scheduled for MR imaging-guided breast biopsy from 2004 to 2008.

60 ean PSS, IES, and CES-D scores, but only the breast biopsy group had highly abnormal anxiety levels.

61 er, findings from clinical studies, in which breast biopsies have been taken or breast tissue density

62 n's experience with image-guided core-needle breast biopsy (IGCNBB) and compare the pathologic result

63 From diagnosed breast biopsy images from two hospitals, we obtained 392

64 Study of pathologists who interpret breast biopsies in clinical practices in 8 US states.

65 ng may have potentially obviated unnecessary breast biopsies in six of eight lesions (P = .031).

66 the extent of lobule regression on a benign breast biopsy in 85 patients who developed breast cancer

67 uary 28, 2010, women undergoing percutaneous breast biopsy in an academic medical center were recruit

68 l threshold of breast cancer risk to perform breast biopsy in order to maximize a patient's total qua

69 reotactic coring excisional biopsy (Advanced Breast Biopsy Instrument [ABBI]), and wire-localized bio

70 Stereotactic core needle breast biopsy is a reproducible and reliable alternative

71 o these data, US-guided vacuum-assisted core breast biopsy is accurate.

72 Mammography following stereotactic breast biopsy is important to document the location and

73 Stereotactic core-needle breast biopsy is widely used to obtain tissue for defini

74 ts suggest that gene expression profiling of breast biopsies may become a valuable method for adequat

75 lts of this retrospective study suggest that breast biopsy may be avoided in women with palpable abno

76 S-D score did not differ significantly among breast biopsy (mean score, 15; 95% CI: 13, 17), hepatic

77 Minimally invasive breast biopsy (MIBB) rates remain well below guideline r

78 MRI examinations performed prior to breast biopsy; MRI results were interpreted at each site

79 mammary epithelial cells (n = 2) and benign breast biopsies (n = 21), BC cell lines (n = 7) and mali

80 n = 21), BC cell lines (n = 7) and malignant breast biopsies (n = 25) showed increased expression of

81 000 resynthesized ssODNs stratified healthy, breast biopsy-negative, and -positive women.

82 Although the breast biopsies on CEE were less commonly diagnosed as c

83 to identify women older than 66 years with a breast biopsy (open or minimally invasive) and subsequen

84 3 or 4 breast density and either a previous breast biopsy or a family history of breast cancer.

85 OR], 2.09; 95% CI, 1.92-2.28), postdiagnosis breast biopsies (OR, 1.74; 95% CI, 1.57-1.93), postdiagn

86 .001), education (OR, 1.22; P = .01), prior breast biopsy (OR, 2.16; P < .001), and residing in Conn

87 Breast biopsy patients had a significantly higher mean S

88 PSS ratings of breast biopsy patients were significantly higher (mean s

89 with a mean score of 26 (95% CI: 23, 29) for breast biopsy patients, 23 (95% CI: 18, 28) for hepatic

90 Results of 111 consecutive image-guided breast biopsies performed for microcalcifications deemed

91 otactic and ultrasonographically guided core breast biopsies performed from 2001 to 2005 were analyze

92 lence of occult breast carcinoma in surgical breast biopsies performed on nonpalpable breast lesions

93 ay facilitate histopathologic diagnosis from breast biopsies performed with imaging guidance.

94 term quality of life related to percutaneous breast biopsy procedures.

95 tional, vacuum-assisted and automated needle breast biopsies produced no distortion or suspicious int

96 table histopathologic result of percutaneous breast biopsy, provided that careful radiologic-histopat

97 d, traditionally used as a level above which breast biopsy recommended, has been generalized to all p

98 mily history of breast cancer and a previous breast biopsy, regardless of breast density.

99 short-interval follow-up recommendations or breast biopsies, respectively.

100 ly history of breast cancer; previous benign breast biopsy result; high breast density; and, for youn

101 adiologic-pathologic-concordant percutaneous breast biopsy results could return to annual screening.

102 arison was made with mammographically guided breast biopsy results in 1,294 patients without breast c

103 Fifty-eight frozen breast biopsy samples were used for these investigations

104 Prior breast biopsy, second-degree relatives with breast cance

105 125I-labeled VIP bound with high affinity to breast biopsy sections.

106 nalysis, based on interpretation of a single breast biopsy slide per case, predicts a low likelihood

107 gnostic interpretation was based on a single breast biopsy slide, overall agreement between the indiv

108 Thus, the finding of ADH in a core needle breast biopsy specimen actually may represent a sample o

109 We reviewed benign breast-biopsy specimens from 1396 women enrolled in the

110 and increasing availability of MR-compatible breast biopsy systems, MRI of the breast is rapidly gain

111 Widespread acceptance of percutaneous breast biopsy techniques represents the most important p

112 s, thereby reducing the number of excisional breast biopsies that are performed.

113 tory of breast cancer, and history of benign breast biopsy), the estimated population attributable fr

114 In 495 stereotactic breast biopsies, the mammographic appearance of the biop

115 g-guided 9-gauge vacuum-assisted core-needle breast biopsy to be a reasonable alternative to MR imagi

116 HER-2/neu amplification in benign breast biopsies was associated with an increased risk of

117 MR imaging-guided breast biopsy was canceled due to lesion nonvisualizatio

118 Prior breast biopsy was more strongly associated with the risk

119 ions; 14-gauge, directional, vacuum-assisted breast biopsy was performed in 40 lesions.

120 women (aged 32-98 years) undergoing BSGI and breast biopsy was performed.

121 Breast biopsies were based on clinical findings.

122 Breast biopsies were more frequent in the CEE group (cum

123 In vivo breast biopsies were performed with the freehand techniq

124 Results from 1,400 consecutive core-needle breast biopsies were reviewed.

125 49 years; range, 26-70 years) scheduled for breast biopsy were included.

126 US-guided, vacuum-assisted breast biopsy with an 11-gauge device was performed in 7

127 ere found between SIFU and RTAS after benign breast biopsy with no significant differences in stage,

128 logic results with wire-localized excisional breast biopsy (WLEBB) for patients with positive cores a